An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity

Clinical article

Restricted access

Object

Despite improvements in the medical and surgical management of patients with glioblastoma, tumor recurrence remains inevitable. For recurrent glioblastoma, however, the clinical value of a second resection remains uncertain. Specifically, what proportion of contrast-enhancing recurrent glioblastoma tissue must be removed to improve overall survival and what is the neurological cost of incremental resection beyond this threshold?

Methods

The authors identified 170 consecutive patients with recurrent supratentorial glioblastomas treated at the Barrow Neurological Institute from 2001 to 2011. All patients previously had a de novo glioblastoma and following their initial resection received standard temozolomide and fractionated radiotherapy.

Results

The mean clinical follow-up was 22.6 months and no patient was lost to follow-up. At the time of recurrence, the median preoperative tumor volume was 26.1 cm3. Following re-resection, median postoperative tumor volume was 3.1 cm3, equating to an 87.4% extent of resection (EOR). The median overall survival was 19.0 months, with a median progression-free survival following re-resection of 5.2 months. Using Cox proportional hazards analysis, the variables of age, Karnofsky Performance Scale (KPS) score, and EOR were predictive of survival following repeat resection (p = 0.0001). Interestingly, a significant survival advantage was noted with as little as 80% EOR. Recursive partitioning analysis validated these findings and provided additional risk stratification at the highest levels of EOR. Overall, at 7 days after surgery, a deterioration in the NIH stroke scale score by 1 point or more was observed in 39.1% of patients with EOR ≥ 80% as compared with 16.7% for those with EOR < 80% (p = 0.0049). This disparity in neurological morbidity, however, did not endure beyond 30 days postoperatively (p = 0.1279).

Conclusions

For recurrent glioblastomas, an improvement in overall survival can be attained beyond an 80% EOR. This survival benefit must be balanced against the risk of neurological morbidity, which does increase with more aggressive cytoreduction, but only in the early postoperative period. Interestingly, this putative EOR threshold closely approximates that reported for newly diagnosed glioblastomas, suggesting that for a subset of patients, the survival benefit of microsurgical resection does not diminish despite biological progression.

Abbreviations used in this paper:EOR = extent of resection; ICC = intraclass correlation coefficient; KPS = Karnofsky Performance Scale; NIHSS = NIH Stroke Scale; RPA = recursive partitioning analysis.
Article Information

Contributor Notes

Address correspondence to: Nader Sanai, M.D., c/o Neuroscience Publications, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 W. Thomas Rd., Phoenix, AZ 85013. email: neuropub@dignityhealth.org.Please include this information when citing this paper: published online January 31, 2014; DOI: 10.3171/2013.12.JNS13184.
Headings
References
  • 1

    Barker FG IIChang SMGutin PHMalec MKMcDermott MWPrados MD: Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:7097231998

    • Search Google Scholar
    • Export Citation
  • 2

    Berger MSCohen WAOjemann GA: Correlation of motor cortex brain mapping data with magnetic resonance imaging. J Neurosurg 72:3833871990

    • Search Google Scholar
    • Export Citation
  • 3

    Bloch OHan SJCha SSun MZAghi MKMcDermott MW: Impact of extent of resection for recurrent glioblastoma on overall survival. Clinical article. J Neurosurg 117:103210382012

    • Search Google Scholar
    • Export Citation
  • 4

    Brott TAdams HP JrOlinger CPMarler JRBarsan WGBiller J: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20:8648701989

    • Search Google Scholar
    • Export Citation
  • 5

    Chaichana KLZadnik PWeingart JDOlivi AGallia GLBlakeley J: Multiple resections for patients with glioblastoma: prolonging survival. Clinical article. J Neurosurg 118:8128202013

    • Search Google Scholar
    • Export Citation
  • 6

    Clarke JLEnnis MMYung WKChang SMWen PYCloughesy TF: Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. Neuro Oncol 13:111811242011

    • Search Google Scholar
    • Export Citation
  • 7

    Dirks PBernstein MMuller PJTucker WS: The value of reoperation for recurrent glioblastoma. Can J Surg 36:2712751993

  • 8

    Fleiss JL: The Design and Analysis of Clinical Experiments New YorkWiley1986

  • 9

    Goldstein LBBertels CDavis JN: Interrater reliability of the NIH stroke scale. Arch Neurol 46:6606621989

  • 10

    Guyotat JSignorelli FFrappaz DMadarassy GRicci ACBret P: Is reoperation for recurrence of glioblastoma justified?. Oncol Rep 7:8999042000

    • Search Google Scholar
    • Export Citation
  • 11

    Hardesty DASanai N: The value of glioma extent of resection in the modern neurosurgical era. Front Neurol 3:1402012

  • 12

    Harsh GR IVLevin VAGutin PHSeager MSilver PWilson CB: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21:6156211987

    • Search Google Scholar
    • Export Citation
  • 13

    Hegi MEDiserens ACGorlia THamou MFde Tribolet NWeller M: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:99710032005

    • Search Google Scholar
    • Export Citation
  • 14

    Helseth RHelseth EJohannesen TBLangberg CWLote KRønning P: Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 122:1591672010

    • Search Google Scholar
    • Export Citation
  • 15

    Hess KR: Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42:2272311999

  • 16

    Kido DKLeMay MLevinson AWBenson WE: Computed tomographic localization of the precentral gyrus. Radiology 135:3733771980

  • 17

    Kline P: The Handbook of Psychological Testing ed 2LondonRoutledge2000

  • 18

    Lacroix MAbi-Said DFourney DRGokaslan ZLShi WDeMonte F: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:1901982001

    • Search Google Scholar
    • Export Citation
  • 19

    Louis DNOhgaki HWiestler ODCavenee WKBurger PCJouvet A: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:971092007

    • Search Google Scholar
    • Export Citation
  • 20

    Mandl ESDirven CMBuis DRPostma TJVandertop WP: Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol 69:5065092008

    • Search Google Scholar
    • Export Citation
  • 21

    McGirt MJMukherjee DChaichana KLThan KDWeingart JDQuinones-Hinojosa A: Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65:4634702009

    • Search Google Scholar
    • Export Citation
  • 22

    Mineo JFBordron ABaroncini MRamirez CMaurage CABlond S: Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien) 149:2452532007

    • Search Google Scholar
    • Export Citation
  • 23

    Pinsker MLumenta C: Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62:43472001

  • 24

    Pouratian NBookheimer SY: The reliability of neuroanatomy as a predictor of eloquence: a review. Neurosurg Focus 28:2E32010

  • 25

    Sanai NPolley MYMcDermott MWParsa ATBerger MS: An extent of resection threshold for newly diagnosed glioblastomas. Clinical article. J Neurosurg 115:382011

    • Search Google Scholar
    • Export Citation
  • 26

    Sanai NSnyder LAHonea NJCoons SWEschbacher JMSmith KA: Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade gliomas. Clinical article. J Neurosurg 115:7407482011

    • Search Google Scholar
    • Export Citation
  • 27

    Skirboll SSOjemann GABerger MSLettich EWinn HR: Functional cortex and subcortical white matter located within gliomas. Neurosurgery 38:6786851996

    • Search Google Scholar
    • Export Citation
  • 28

    Stupp RMason WPvan den Bent MJWeller MFisher BTaphoorn MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:9879962005

    • Search Google Scholar
    • Export Citation
  • 29

    Tavakol MDennick R: Making sense of Cronbach's alpha. Int J Med Ed 2:53552011

  • 30

    Weir JP: Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM. J Strength Cond Res 19:2312402005

    • Search Google Scholar
    • Export Citation
  • 31

    Wen PYKesari S: Malignant gliomas in adults. N Engl J Med 359:4925072008

  • 32

    Williams LSYilmaz EYLopez-Yunez AM: Retrospective assessment of initial stroke severity with the NIH Stroke Scale. Stroke 31:8588622000

    • Search Google Scholar
    • Export Citation
TrendMD
Cited By
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 40 40 40
Full Text Views 1009 425 15
PDF Downloads 406 215 10
EPUB Downloads 0 0 0
PubMed
Google Scholar